FDA approves Xolremdi capsules for WHIM syndrome, boosting neutrophil & lymphocyte counts. First therapy for this rare immunodeficiency disorder. Potential sales forecasted at $54.6M in 2024, rising to $450.9M by 2027.
Coca-Cola s stock gains after sales top forecasts, as prices and volume rose Case volume growth was strongest in juice, value-added dairy and plant-based beverages.
Marriott s stock drops.
Coca-Cola Stock Has Gone Flat. Is it Time to Buy? The beverage company s steady sales growth makes it an attractive hedge.
Marriott s stock drops as fourth-quarter revenue falls short .
Coca-Cola Stock Has Gone Flat. Is it Time to Buy? The beverage company s steady sales growth makes it an attractive hedge.
Marriott s stock drops as fourth-quarter revenue falls short .